$66.30
2.56%
Nasdaq, Jul 18, 10:00 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Stock price

$66.30
+1.64 2.54% 1M
+7.84 13.41% 6M
+11.02 19.93% YTD
+4.95 8.07% 1Y
+35.31 113.94% 3Y
+36.92 125.66% 5Y
-2.50 3.63% 10Y
-67.98 50.63% 20Y
Nasdaq, Closing price Fri, Jul 18 2025
-1.74 2.56%
ISIN
US00182C1036
Symbol
ANIP
Sector
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.9b
Net debt
$467.6m
Cash
$155.2m
Shares outstanding
21.7m
Valuation (TTM | estimate)
P/E
negative | 10.0
P/S
1.8 | 1.8
EV/Sales
2.4 | 2.4
EV/FCF
28.6
P/B
3.2
Financial Health
Equity Ratio
33.4%
Return on Equity
-4.7%
ROCE
2.7%
ROIC
3.6%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$811.5m | $803.8m
EBITDA
$119.7m | $204.7m
EBIT
$29.0m | $202.8m
Net Income
$-6.4m | $144.2m
Free Cash Flow
$66.6m
Growth (TTM | estimate)
Revenue
56.9% | 30.8%
EBITDA
7.1% | 190.1%
EBIT
-44.2% | 7,039.8%
Net Income
-120.9% | 815.5%
Free Cash Flow
-36.4%
Margin (TTM | estimate)
Gross
60.2%
EBITDA
14.7% | 25.5%
EBIT
3.6%
Net
-0.8% | 17.9%
Free Cash Flow
8.2%
More
EPS
$-0.3
FCF per Share
$3.1
Short interest
11.7%
Employees
897
Rev per Employee
$680.0k
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
812 812
57% 57%
100%
- Direct Costs 323 323
68% 68%
40%
488 488
50% 50%
60%
- Selling and Administrative Expenses 326 326
88% 88%
40%
- Research and Development Expense 55 55
42% 42%
7%
120 120
7% 7%
15%
- Depreciation and Amortization 91 91
52% 52%
11%
EBIT (Operating Income) EBIT 29 29
44% 44%
4%
Net Profit -6.44 -6.44
121% 121%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
19 days ago
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA.
Neutral
GlobeNewsWire
about one month ago
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress
Neutral
GlobeNewsWire
about 2 months ago
PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 897
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today